Lipoprotein A: The Essential Cholesterol Test Missing from Public Health Systems
Despite growing international consensus among US and European medical societies that everyone should measure Lipoprotein A (Lp(a)) at least once, Spain's public health system largely fails to offer this critical cardiovascular risk marker. Lp(a) levels are primarily genetically determined, affecting approximately 20% of the European population with elevated readings. High levels significantly increase the risk of heart attacks, strokes, and aortic valve calcification, even when other cholesterol markers appear normal. The article highlights a significant gap in preventive care, attributing the lack of routine testing to systemic heterogeneity, varying hospital protocols, and inconsistent physician awareness regarding interpretation. Daniel Escribano, a specialist at the Spanish Society of Family and Community Medicine, notes that access depends heavily on local management and specific medical specialties rather than standardized national guidelines. A contributing factor to this neglect is the current absence of specific treatments designed solely to lower Lp(a) levels. Consequently, many individuals remain unaware of their heightened genetic risk, missing opportunities for early intervention and aggressive management of other cardiovascular factors. This disparity underscores a broader issue in public health prioritization and the integration of modern lipidology into primary care practices across different autonomous communities in Spain.
Wire timeline
Lipoprotein A: The Essential Cholesterol Test Missing from Public Health Systems
Despite growing international consensus among US and European medical societies that everyone should measure Lipoprotein A (Lp(a)) at least once, Spain's public health system largely fails to offer this critical cardiovascular risk marker. Lp(a) levels are primarily genetically determined, affecting approximately 20% of the European population with elevated readings. High levels significantly increase the risk of heart attacks, strokes, and aortic valve calcification, even when other cholesterol markers appear normal. The article highlights a significant gap in preventive care, attributing the lack of routine testing to systemic heterogeneity, varying hospital protocols, and inconsistent physician awareness regarding interpretation. Daniel Escribano, a specialist at the Spanish Society of Family and Community Medicine, notes that access depends heavily on local management and specific medical specialties rather than standardized national guidelines. A contributing factor to this neglect is the current absence of specific treatments designed solely to lower Lp(a) levels. Consequently, many individuals remain unaware of their heightened genetic risk, missing opportunities for early intervention and aggressive management of other cardiovascular factors. This disparity underscores a broader issue in public health prioritization and the integration of modern lipidology into primary care practices across different autonomous communities in Spain.
elpais